Prescott Group Capital Management L.L.C. Has $1.82 Million Stock Holdings in Encompass Health Co. (NYSE:EHC)

Prescott Group Capital Management L.L.C. lifted its holdings in Encompass Health Co. (NYSE:EHC - Free Report) by 43.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 19,753 shares of the company's stock after buying an additional 6,000 shares during the quarter. Prescott Group Capital Management L.L.C.'s holdings in Encompass Health were worth $1,824,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in EHC. TD Private Client Wealth LLC boosted its holdings in Encompass Health by 2,870.0% in the third quarter. TD Private Client Wealth LLC now owns 7,336 shares of the company's stock valued at $709,000 after acquiring an additional 7,089 shares during the last quarter. Los Angeles Capital Management LLC grew its holdings in Encompass Health by 532.4% during the 3rd quarter. Los Angeles Capital Management LLC now owns 50,290 shares of the company's stock worth $4,860,000 after acquiring an additional 42,338 shares during the period. Pathstone Holdings LLC raised its position in shares of Encompass Health by 54.5% during the 3rd quarter. Pathstone Holdings LLC now owns 21,022 shares of the company's stock valued at $2,032,000 after acquiring an additional 7,412 shares during the last quarter. Meeder Asset Management Inc. lifted its stake in shares of Encompass Health by 43.8% in the 3rd quarter. Meeder Asset Management Inc. now owns 66,405 shares of the company's stock valued at $6,417,000 after purchasing an additional 20,242 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of Encompass Health by 1.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,673,610 shares of the company's stock worth $161,781,000 after purchasing an additional 20,547 shares during the last quarter. Institutional investors own 97.25% of the company's stock.

Remove Ads

Encompass Health Stock Performance

NYSE EHC traded down $2.14 on Tuesday, hitting $96.98. 585,805 shares of the stock were exchanged, compared to its average volume of 634,477. The company has a market capitalization of $9.77 billion, a PE ratio of 21.74, a P/E/G ratio of 2.31 and a beta of 0.92. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.05 and a quick ratio of 1.04. The business's fifty day moving average is $97.09 and its 200 day moving average is $96.86. Encompass Health Co. has a 52 week low of $74.27 and a 52 week high of $104.55.

Encompass Health (NYSE:EHC - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $1.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.12. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. Research analysts anticipate that Encompass Health Co. will post 4.8 EPS for the current fiscal year.

Encompass Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Tuesday, April 1st will be issued a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.70%. The ex-dividend date is Tuesday, April 1st. Encompass Health's payout ratio is presently 15.25%.

Wall Street Analysts Forecast Growth

EHC has been the topic of several analyst reports. KeyCorp increased their target price on Encompass Health from $117.00 to $120.00 and gave the company an "overweight" rating in a research note on Monday, February 10th. William Blair reaffirmed an "outperform" rating on shares of Encompass Health in a research note on Friday, February 7th. Royal Bank of Canada reissued an "outperform" rating and set a $110.00 price objective on shares of Encompass Health in a research note on Tuesday, February 11th. StockNews.com raised shares of Encompass Health from a "hold" rating to a "buy" rating in a research note on Saturday, February 15th. Finally, Barclays boosted their price target on shares of Encompass Health from $116.00 to $118.00 and gave the company an "overweight" rating in a report on Friday, February 7th. Ten investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $107.67.

Insider Activity at Encompass Health

In other Encompass Health news, CAO Andrew L. Price sold 5,042 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $98.29, for a total value of $495,578.18. Following the transaction, the chief accounting officer now directly owns 69,164 shares of the company's stock, valued at $6,798,129.56. This represents a 6.79 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.10% of the stock is owned by company insiders.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.